The assessment of local tolerance, acute toxicity, and DNA biodistribution following particle-mediated delivery of a DNA vaccine to minipigs.
Particle-mediated DNA delivery was used to administer a DNA vaccine against Hepatitis B to minipigs. The study represented one arm of the safety evaluation program for this product and was designed to assess local tolerance, acute toxicity, and biodistribution of the DNA plasmid. The vaccine was given to 4 groups of minipigs that were sacrificed at 2, 28, 56, or 141 days after treatment. The procedure was well tolerated with mild local skin reactions at 2 days postdosing and no evidence of systemic toxicity. By 28 days the skin lesions had regressed apart from a low grade perivascular mononuclear cell infiltrate in the upper dermis, together with a small number of phagocytosed gold particles. This infiltrate persisted up to 141 days. The expressed HBsAg was detected by immunohistochemistry in keratinocytes (usually in association with an intranuclear gold particle) at 2 days but not at later time points. Polymerase chain reaction (PCR) was used to assay treatment sites and selected internal organs to evaluate biodistribution and persistence of the DNA plasmid. At 2 days the plasmid was detected in the treatment sites and also in the inguinal lymph nodes. At day 57 it was present in the treatment sites only and by day 141 appeared to have cleared. The results from this study demonstrate that particle-mediated gene delivery was well tolerated in the minipig. The biodistribution and persistence of the plasmid was within acceptable limits for this type of vaccine. As the minipig is regarded as a good model for humans these data support the concept that particle-mediated DNA delivery will be safe in human clinical applications.
Pilling
Andrew M
AM
Pathology Department, Safety Assessment, GlaxoSmithKline, Ware, Hertfordshire, United Kingdom. amp1069@gsk.com
Harman
Risa M
RM
Jones
Stewart A
SA
McCormack
Nicola A M
NA
Lavender
Debbie
D
Haworth
Richard
R
D000818:Animals; D019470:Biolistics; D004247:DNA / Q000737:chemistry; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000737:chemistry; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D007150:Immunohistochemistry; D015603:Keratinocytes / Q000737:chemistry; D008297:Male; D010957:Plasmids / Q000737:chemistry / Q000235:genetics; D016133:Polymerase Chain Reaction; D012867:Skin / Q000473:pathology*; D013552:Swine; D013556:Swine, Miniature; D014018:Tissue Distribution; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000633:toxicity*
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; D004247:DNA